Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2007

Nanoviricides and Walter Reed Team Up to Fight Dengue Fever

  • NanoViricides signed a CRADA with the Walter Reed Army Institute of Research (WRAIR). The joint R&D effort will focus on creating new treatments for dengue fever using NanoViricides’ virus-killing nanomedicine technology.

    "This collaboration will leverage Walter Reed’s extensive experience in dengue fever research with our unique nanoviricide™ technology platform for creating antiviral medications," says president, Anil Diwan.

    The company’s TheraCour technologies are used to develop nanotechnology-based targeted antiviral therapeutics.  



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »